Compugen Has Licensed Selexis’ Cell Line-Based Protein Expression Platform for the Development of Antibody-Based Therapeutics

Selexis SUREtechnology Platform™ in use for the generation of high-performance research cell banks for Compugen

GENEVA—()—Selexis SA, a pioneering life sciences company and a global leader in mammalian cell line generation technology, announced today that Compugen Ltd. has taken a license to the Selexis SUREtechnology Platform™ for use in generating high-performance research cell banks (RCBs). A leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, Compugen will leverage Selexis’ mammalian cell line-based protein expression platform to develop antibody-based therapeutics targeting certain cancers, including to support further advancement of COM701.

Compugen’s lead immuno-oncology product candidate, COM701, is a humanized hybridoma antibody that binds with high affinity to PVRIG, a novel B7/CD28-like immune checkpoint target candidate discovered by Compugen, blocking its interaction with PVRL2. The candidate is currently in preclinical development with an investigational new drug (IND) application filing with the U.S. Food and Drug Administration expected towards the end of the first quarter of 2018.

“Our agreement with Compugen is indicative of Selexis’ strength in protein expression and our leadership in bringing an innovative technology solution to our partners,” said Yemi Onakunle, PhD, Selexis vice president, business development and licensing. “It is rewarding for us to play a role in the important research and development efforts ongoing at Compugen and we value the opportunity to continue to play a role in enabling our partners to bring much needed treatment options to patients.”

“The Selexis SUREtechnology Platform enabled us to quickly generate a high-expressing cell line to support COM701 development activities,” said John Hunter, PhD, Compugen vice president of antibody R&D. “We look forward to working with the Selexis team as we advance future programs into the clinic.”

Selexis’ proprietary and high performance SUREtechnology Platform facilitates the rapid, stable and cost-effective production of virtually any recombinant protein including those that are difficult to express in other systems. It also provides seamless integration of the biologics and vaccine development continuum, spanning discovery to commercialization.


Media Inquiries for Selexis
Sam Brown Inc.
Mike Beyer, +1 312-961-2502
Company Inquiries for Selexis
Robert Meister, +1 602-953-1716
Head, Corporate Communications


Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.

Selexis SA

Selexis SA is a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, providing unparalleled proprietary technology and the highly-specialized expertise that is necessary to translate scientific innovation into life-saving medicines for patients. Selexis’ SUREtechnology Platform™ facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the bioproduction continuum, spanning discovery to commercialization. With more than 100 partners worldwide, 95 drug products in clinical development and three commercial products utilizing Selexis-generated cell lines, the Company has a history of empowering scientists and biopharmaceutical companies around the world to realize the full potential of their research.